Marc De Hert | Psychiatrist.com

Original Research

Do Advanced Statistical Techniques Really Help in the Diagnosis of the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotics?

Article

Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent? A Literature Review

Original Research

Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges

Article

Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder

Original Research

Prediabetes in Patients Treated With Antipsychotic Drugs

Meta-Analysis

Prevalence and Predictors of Type 2 Diabetes Mellitus in People With Bipolar Disorder: A Systematic Review and Meta-Analysis

Article

Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances: Results From a Comprehensive, Naturalistic Screening Program

Letter to the Editor

Reply to Applicability of the Oral Glucose Tolerance Test in Assessing Prevalence and Incidence of Diabetes Mellitus in Schizophrenia

Original Research

Screening for Diabetes and Other Metabolic Abnormalities in Patients With Schizophrenia and Schizoaffective Disorder: Evaluation of Incidence and Screening Methods.

Meta-Analysis

Topiramate-Antipsychotic Cotreatment

Topiramate is known to cause weight loss, but it's also known to cause adverse psychiatric side effects. So how would topiramate affect patients already taking antipsychotics? Read this meta-analysis...

Original Research

Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder